SEARCH

SEARCH BY CITATION

References

  • 1
    Ohtsuki M, Terui T, Ozawa A et al. Guideline and safety manual for use of biologic agents in psoriasis (the 2011 version). Jpn J Dermatol 2011; 121: 15611572.
  • 2
    Ohtsuki M, Terui T, Ozawa A et al. The guideline and safety manual for use of anti-TNFα agents in psoriasis. Jpn J Dermatol 2010; 120: 163171.
  • 3
  • 4
    Iwatsuki K, Terui T, Ozawa A et al. The guidelines for diagnosis and treatment of generalized pustular psoriasis 2010 (Treatment guidelines incorporating TNFα inhibitors). Jpn J Dermatol 2010; 120: 815839.
  • 5
    Asahina A, Nakagawa H, Etoh T, Ohtsuki M. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase 2/3 randomized controlled study. J Dermatol 2010; 37: 299310.
  • 6
    Torii H, Nakagawa H, Japanese Infliximab Study Investigators. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 2010; 59: 4049.
  • 7
    Igarashi A, Kato T, Kato M, Song M, Nakagawa H, Japanese Ustekianmab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol 2012; 39: 242252.
  • 8
    Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005; 152: 861867.
  • 9
    Menter A, Gottlieb A, Feldman SR et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826850.
  • 10
    Menter A, Korman NJ, Elmets CA et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011; 65: 137174.
  • 11
    Smith CH, Anstey AV, Barker JNWN et al. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 9871019.
  • 12
    Pathirana D, Ormerod AD, Saiag P et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl. 2): 570.
  • 13
    Nast A, Boehncke WH, Mrowietz U et al. S3-guidelines on the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges 2012; 10 (Suppl. 2): S1S95.
  • 14
    The Prevention Committee of the Japanese Society for Tuberculosis. Treatment guidelines for latent tuberculosis. Kekkeku (Jpn J of Tuberculosis) 2013; 88: 497512.
  • 15
    Tsubouchi H, Kumada H, Kiyosawa K et al. Prevention of immunosuppressive therapy- or chemotherapy-induced reactivation of hepatitis B virus infection—Joint report of the intractable liver diseases study group of Japan and the Japanese study group of the standard antiviral therapy for viral hepatitis. Kanzo (Jpn J Hepatol) 2009; 50: 3842.
  • 16
    Asahina Y, Izumi N, Oketani M et al. Guidelines for the management of hepatitis B virus infection. Kanzo (Jpn J Hepatol), 2013; 54: 402472.
  • 17
    Torii H, Nakagawa H, Japanese Infliximab Study Investigators. Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J Dermatol 2011; 38: 321334.